PETOR is a proton-pump inhibitor, indicated for gastro-esophageal reflux disease (GERD), ulcers, Zollinger-Ellison Syndrome, and erosive esophagitis. It decreases the amount of acid made in the stomach.
PETOR suppresses the final step in gastric acid production by forming a covalent bond to two sites of the H+/K+- ATPase enzyme system at the secretory surface of the gastric parietal cell.
PETOR is well absorbed that undergoes little first-pass metabolism resulting in an absolute bioavailability of 0approximately 77%. Volume of distribution- 11 to 23.6 L Protein binding- 98% PETOR is extensively metabolized in the liver through the cytochrome P450 (CYP) system. The main metabolic pathway is demethylation, by CYP2C19, with subsequent sulfation; other metabolic pathways include oxidation by CYP3A4. Half-life: 1 hour Clearance: 7.6- 14 L/h
40mg orally once a day, for short-term administration (upto 8 weeks).
Each strip contains 10 tablets.